Vertex Pharmaceuticals Stock Forecast
NASDAQ: VRTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
VRTX analyst consensus
Consensus (32 analysts)
buy
Avg. price target
$571.39+13.00%
- Strong buy 6
- Buy 20
- Hold 5
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 32 Wall Street analysts covering Vertex Pharmaceuticals (2026-10-07), 26 rate the stock a buy or strong buy, 5 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $571.39, with a high estimate of $672.00 and a low estimate of $350.00. The average target implies upside of 13.0% from the current price of $505.64.
The spread between the highest and lowest targets is 92.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for VRTX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 6 | 19% |
| Buy | 20 | 63% |
| Hold | 5 | 16% |
| Sell | 1 | 3% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $350.00 | -30.78% |
| Average target | $571.39 | +13.00% |
| High target | $672.00 | +32.90% |